Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crovalimab versus eculizumab in complement inhibitor-naive paroxysmal nocturnal hemoglobinuria
NL-OMON60551Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of crovalimab and eculizumab in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Roche. Primary endpoints: Transfusion avoidance and Hemolysis control. Started Jun 2021; status: completed.
02
Drugs
crovalimabeculizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NL-OMON60551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60551.